Research programme: peptide-drug conjugates - JCR Pharmaceuticals/PeptiDream/Takeda Pharmaceutical
Latest Information Update: 08 Dec 2022
At a glance
- Originator JCR Pharmaceuticals; PeptiDream; Takeda
- Developer Takeda
- Class Drug conjugates; Peptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Neuromuscular disorders
Most Recent Events
- 08 Dec 2022 Peptide-drug conjugates - JCR Pharmaceuticals/PeptiDream/Takeda Pharmaceutical is available for licensing as of 06 Dec 2022. https://www.peptidream.com/pipeline/progress-of-programs.html
- 06 Dec 2022 Preclinical trials in Neuromuscular disorders in Japan (unspecified route) before December 2022 (PeptiDream pipeline, December 2022)
- 22 Dec 2020 PeptiDream and Takeda Pharmaceutical Company enter into research and license agreement for Neuromuscular diseases